Physician profile
Lisa A Scott
NPI 1326387887
$2,652.41
in general payments reported to CMS, 2019-2025
29 companies · $535 in 2025
The $535 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $276 · 2022: $177 · 2023: $724 · 2024: $941 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,200.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $567.24 | 2024-2025 | Surgicount, Stryker, 1788 |
| Abbvie INC. | $345.78 | 2021-2025 | |
| Glaxosmithkline, LLC. | $232.07 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Novo Nordisk INC | $231.08 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $211.49 | 2023-2025 | Rapidvac, Intellis Adaptivestim, Inceptiv |
| Amgen INC. | $102.98 | 2021-2024 | Otezla, Repatha, Prolia |
| Lilly USA, LLC | $101.74 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $92.39 | 2023-2025 | |
| Exact Sciences Corporation | $79.24 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.38 | 2023-2024 | Jardiance |
| Sumitomo Pharma America, INC. | $65.80 | 2023-2024 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $59.69 | 2021-2023 | Farxiga |
| Corium, LLC | $53.56 | 2023 | Azstarys |
| Neos Therapeutics, LP | $51.05 | 2023-2025 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $48.18 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $44.28 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $39.27 | 2023-2024 | Rexulti |
| Phadia US INC. | $35.07 | 2024 | Immunocap |
| Inspire Medical Systems, INC. | $34.01 | 2024-2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $28.42 | 2021-2022 | |
| Almatica Pharma LLC | $27.30 | 2022 | |
| Vanda Pharmaceuticals INC. | $21.82 | 2021 | |
| Noven Therapeutics, LLC | $18.31 | 2024 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $17.12 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.56 | 2021 | |
| Daiichi Sankyo INC. | $14.75 | 2021 | |
| Tris Pharma INC | $14.62 | 2024 | Dyanavel Xr |
| Phathom Pharmaceuticals, INC. | $14.19 | 2025 | Voquezna |
| Eisai INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.